{
    "clinical_study": {
        "@rank": "52061", 
        "arm_group": [
            {
                "arm_group_label": "Generic latanoprost", 
                "arm_group_type": "Experimental", 
                "description": "1 eye drop hs"
            }, 
            {
                "arm_group_label": "Brand-name latanoprost", 
                "arm_group_type": "Active Comparator", 
                "description": "1 eye drop hs"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate and compare efficacy and tolerability of the\n      brand-name latanoprost and one of its generic version in subjects with primary open angle\n      glaucoma or ocular hypertension.\n\n      This randomized, double-blinded, cross-over design study has a 4 months follow-up. There are\n      two periods of 8 weeks. During the first period, subjects put brand-name latanoprost in one\n      eye and the generic version in the other one. In the second period, drops are switched from\n      one eye to the other. There are intraocular pressure measurements (diurnal curves) on day 0\n      (before treatment), at 8 weeks (at the end of first period) and at 16 weeks (at the end of\n      second period). Variations of intraocular pressure in each eye will be evaluated."
        }, 
        "brief_title": "Efficacy of the Brand-name Latanoprost and One of Its Generic Version in Primary Open Angle Glaucoma and Ocular Hypertension", 
        "condition": [
            "Primary Open Angle Glaucoma", 
            "Ocular Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. >18 years old\n\n          2. Primary open angle glaucoma, glaucoma suspect or ocular hypertension\n\n          3. Bilateral\n\n          4. Without any treatment or treated with latanoprost or another prostaglandin analog\n\n          5. Intraocular pressure >21mmHg (without treatment or after a washout period)\n\n        Exclusion Criteria:\n\n          1. Intraocular pressure >30mmHg\n\n          2. Secondary glaucoma (uveitic, neovascular, traumatic ) or congenital glaucoma\n\n          3. Pseudoexfoliation syndrome\n\n          4. Pigmentary dispersion syndrome or Pigmentary glaucoma\n\n          5. Severe glaucoma; Cup-to-disc ratio \u22659/10 OU Loss of central visual field (central\n             10\u00b0)\n\n          6. Use of other topical medication to lower intraocular pressure\n\n          7. Pregnancy and breast-feeding\n\n          8. Being allergic to latanoprost or benzalkonium chloride (BAK)\n\n          9. Current use of acetazolamide (Diamox)\n\n         10. Changes of systemic doses of beta-blockers during study\n\n         11. Recent use of topical corticosteroids (<1 month)\n\n         12. Contact lens wearer\n\n         13. Closed angle at gonioscopy or past angle closure glaucoma\n\n         14. Filtration surgery (example. : trabeculectomy)\n\n         15. Selective Laser Trabeculoplasty (SLT) or Argon Laser Trabeculoplasty(ALT)\n\n         16. Recent Intraocular surgery (<3 months)\n\n         17. Refractive surgery\n\n         18. Recent iridotomy or capsulotomy (<3 months)\n\n         19. Past medical history of ocular trauma (example : angle recession)\n\n         20. Past or active uveitis\n\n         21. Herpetic keratitis\n\n         22. Monocular vision"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02047630", 
            "org_study_id": "C13-11-1242"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Generic latanoprost", 
                    "Brand-name latanoprost"
                ], 
                "intervention_name": "Generic latanoprost", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Generic latanoprost", 
                    "Brand-name latanoprost"
                ], 
                "intervention_name": "Brand-name latanoprost", 
                "intervention_type": "Drug", 
                "other_name": "Xalatan"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Latanoprost"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Primary open angle glaucoma", 
            "Ocular hypertension", 
            "latanoprost", 
            "generic", 
            "intraocular pressure"
        ], 
        "lastchanged_date": "January 27, 2014", 
        "location": {
            "contact": {
                "email": "marie-josee.fredette.cha@ssss.gouv.qc.ca", 
                "last_name": "Marie-Jos\u00e9e Fredette, MD, FRCSC", 
                "phone": "418-682-7511", 
                "phone_ext": "4846"
            }, 
            "contact_backup": {
                "email": "marcelle.giasson@fmed.ulaval.ca", 
                "last_name": "Marcelle Giasson, BSc", 
                "phone": "418-682-7511", 
                "phone_ext": "4854"
            }, 
            "facility": {
                "address": {
                    "city": "Qu\u00e9bec", 
                    "country": "Canada", 
                    "state": "Quebec", 
                    "zip": "G1S 4L8"
                }, 
                "name": "Centre universitaire d'ophtalmologie, H\u00f4pital du Saint-Sacrement, CHU de Qu\u00e9bec"
            }, 
            "investigator": {
                "last_name": "Marie-Jos\u00e9e Fredette, MD, FRCSC", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "marie-josee.fredette.cha@ssss.gouv.qc.ca", 
            "last_name": "Marie-Jos\u00e9e Fredette, MD, FRCSC", 
            "phone": "418-682-7511", 
            "phone_ext": "4846"
        }, 
        "overall_contact_backup": {
            "email": "mathieu.mercier.4@ulaval.ca", 
            "last_name": "Mathieu Mercier, MD"
        }, 
        "overall_official": {
            "affiliation": "Centre de recherche du CHU de Qu\u00e9bec; Universit\u00e9 Laval", 
            "last_name": "Marie-Jos\u00e9e Fredette, MD, FRCSC", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Ethics Review Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Goldman applanation tonometry will be used to measure IOP.", 
            "measure": "Change in Intraocular Pressure (IOP)", 
            "safety_issue": "No", 
            "time_frame": "8 weeks, 16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02047630"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Centre Hospitalier Universitaire de Qu\u00e9bec, CHU de Qu\u00e9bec", 
            "investigator_full_name": "Marie-Jos\u00e9e Fredette", 
            "investigator_title": "MD, FRCSC", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in Conjunctival hyperemia", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks, 16 weeks"
            }, 
            {
                "description": "Oxford grading scale", 
                "measure": "Change in corneal staining", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks, 16 weeks"
            }, 
            {
                "measure": "Change in TSS-IOP (Treatment Satisfaction Survey for IntraOcular Pressure)", 
                "safety_issue": "No", 
                "time_frame": "8 weeks, 16 weeks"
            }
        ], 
        "source": "Centre Hospitalier Universitaire de Qu\u00e9bec, CHU de Qu\u00e9bec", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre Hospitalier Universitaire de Qu\u00e9bec, CHU de Qu\u00e9bec", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}